PMID: 11955750
Question: Does escalation of the apical dose change treatment outcome in beta-radiation of posterior choroidal melanomas with 106Ru plaques?
Correct Answer: no

======================= Launch the MCC process =======================
PMID: 11955750
Question: Does escalation of the apical dose change treatment outcome in beta-radiation of posterior choroidal melanomas with 106Ru plaques?

----- GPT's initial response -----
GPT is reasoning the answer...


**1. Question Analysis**
- **Core Content**: The research question seeks to determine whether increasing the apical dose in beta-radiation therapy using 106Ru plaques affects the treatment outcomes for patients with posterior choroidal melanomas.
- **Key Information to Extract**:
  - Comparison of different apical dose levels (specifically 100 Gy vs. 160 Gy).
  - Treatment outcomes such as survival rates, local control, vision preservation, and side effects.
  - Conclusions drawn by the study regarding dose escalation.

**2. Evidence Evaluation**
- **Research Results**: The study treated 48 patients with a median apical dose of 120 Gy. The 5-year survival rates were high (90% overall, 92% disease-specific), and local control was achieved in 90% of cases. The abstract explicitly states, "The treatment outcome does not seem to be capable of improvement by increasing the apical dose."
- **Strength and Reliability**: The study includes a follow-up period of 5.8 years, providing substantial longitudinal data. However, the sample size is relatively small (48 patients), which may limit the generalizability of the findings.
- **Relevance**: The evidence directly addresses the question by comparing outcomes related to different apical dose levels, particularly noting that increasing the dose beyond what was administered did not yield better results.

**3. Conclusion**
Based on the abstract, escalating the apical dose beyond the median of 120 Gy does not enhance treatment outcomes for posterior choroidal melanomas treated with 106Ru plaques. The authors conclude that increasing the apical dose does not improve efficacy, indicating that dose escalation is unlikely to change the treatment outcome positively.

**4. Final Answer**
**My final choice is: "no"**
GPT selected: no

----- Qwen's initial response -----
Qwen is reasoning the answer...


**1. Question Analysis**  
The question asks whether increasing the apical dose (e.g., from 100 Gy to 160 Gy) affects treatment outcomes in beta-radiation therapy for posterior choroidal melanomas using 106Ru plaques. Key points to assess in the abstract:  
- Whether the study compared different apical doses (e.g., 100 vs. 160 Gy).  
- Outcomes (e.g., survival, local control, vision preservation) in relation to apical dose escalation.  

**2. Evidence Evaluation**  
- The study treated 48 patients with a **median apical dose of 120 Gy** (midway between 100 and 160 Gy).  
- The abstract explicitly states: *"The treatment outcome does not seem to be capable of improvement by increasing the apical dose."*  
- Outcomes reported (90% overall survival, 92% disease-specific survival, 90% local control) were comparable to other studies, suggesting no benefit from higher doses.  
- The authors conclude that dose escalation does not improve outcomes and advocate for standardized dosage models.  

**3. Conclusion**  
The studyâ€™s results and conclusion directly address the question. The authors found no evidence that increasing the apical dose (e.g., to 160 Gy) improves treatment outcomes, as outcomes were already favorable at a median dose of 120 Gy. The abstract provides a clear, internally consistent conclusion based on their data.  

**4. Final Answer:**  
**My final choice is: "no"**
Qwen selected: no

----- Deepseek's initial response -----
DeepSeek is reasoning the answer...

**1. Question Analysis**  
The question asks whether increasing the apical dose (e.g., from 100 Gy to 160 Gy) improves treatment outcomes in beta-radiation therapy using 106Ru plaques for posterior choroidal melanomas. Key information to evaluate includes survival rates, local tumor control, and complications related to dose escalation, as well as explicit conclusions from the study regarding dose optimization.  

**2. Evidence Evaluation**  
- The study treated 48 patients with a median apical dose of 120 Gy (between 100 Gy and 160 Gy).  
- Outcomes included 90% 5-year survival, 92% disease-specific survival, and 90% local control with conservative therapy.  
- The authors explicitly state, "The treatment outcome does not seem to be capable of improvement by increasing the apical dose," indicating no observed benefit from higher doses.  
- Adverse effects (e.g., retinopathy, macular degeneration) were noted but not directly linked to dose escalation in the abstract.  
- The conclusion emphasizes that their results align with other studies and calls for standardized dosing, indirectly supporting that dose escalation does not enhance efficacy.  

**3. Conclusion**  
The evidence strongly suggests that escalating the apical dose does not improve treatment outcomes for posterior choroidal melanomas treated with 106Ru plaques. The authors explicitly reject dose escalation as beneficial, and survival/local control rates remain stable despite varying doses.  

**4. Final Answer**  
**My final choice is: no**
DeepSeek selected: no

Initial consensus: All models selected no

